Crossmark

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours

Crossref DOI link: https://doi.org/10.1038/s41388-018-0228-x

Published Online: 2018-04-27

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Toosi, Behzad M.

El Zawily, Amr

Truitt, Luke

Shannon, Matthew

Allonby, Odette

Babu, Mohan

DeCoteau, John

Mousseau, Darrell

Ali, Mohsin

Freywald, Tanya

Gall, Amanda

Vizeacoumar, Frederick S.

Kirzinger, Morgan W.

Geyer, C. Ronald

Anderson, Deborah H.

Kim, TaeHyung

Welm, Alana L.

Siegel, Peter https://orcid.org/0000-0002-5568-6586
Vizeacoumar, Franco J. https://orcid.org/0000-0002-6452-5207
Kusalik, Anthony

Freywald, Andrew
License Information

Text and Data Mining valid from 2018-04-27
More Information

Article History

Received: 17 May 2017

Revised: 30 January 2018

Accepted: 27 February 2018

First Online: 27 April 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.